1-23795992-C-T
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PS1_ModeratePM2PP3PP5_Very_Strong
The NM_001008216.2(GALE):c.1004G>A(p.Arg335His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000123 in 1,461,700 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R335C) has been classified as Uncertain significance.
Frequency
Consequence
NM_001008216.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GALE | NM_001008216.2 | c.1004G>A | p.Arg335His | missense_variant | 12/12 | ENST00000617979.5 | NP_001008217.1 | |
GALE | NM_000403.4 | c.1004G>A | p.Arg335His | missense_variant | 12/12 | NP_000394.2 | ||
GALE | NM_001127621.2 | c.1004G>A | p.Arg335His | missense_variant | 11/11 | NP_001121093.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GALE | ENST00000617979.5 | c.1004G>A | p.Arg335His | missense_variant | 12/12 | 1 | NM_001008216.2 | ENSP00000483375.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250928Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135706
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461700Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727148
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
UDPglucose-4-epimerase deficiency Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 25, 2023 | Variant summary: GALE c.1004G>A (p.Arg335His) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 250928 control chromosomes. c.1004G>A has been reported in the literature in at least two compound heterozygous newborns with severely reduced enzyme activity in red blood cells, but without obvious clinical symptoms, suggesting that they had the benign- or peripheral form of UDPglucose-4-Epimerase Deficiency (Park_2005), and in at least another individual with epimerase-deficiency galactosemia, however no phenotype details were provided (Henderson_2001). Publications also reported experimental evidence evaluating an impact on protein function, and demonstrated a moderate decrease in UDP-galactose epimerization activity, ranging from ~40 to 70% of the wild-type (Timson_2005, Bang_2009). The following publications have been ascertained in the context of this evaluation (PMID: 19250319, 16302980, 16301867, 11903335). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified for the peripheral form of the disease as likely pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 29, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this missense change affects GALE function (PMID: 16302980, 19250319). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GALE protein function. ClinVar contains an entry for this variant (Variation ID: 2503917). This missense change has been observed in individual(s) with galactosemia (PMID: 16301867). This variant is present in population databases (rs368637540, gnomAD 0.006%). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 335 of the GALE protein (p.Arg335His). - |
GALE-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 03, 2023 | The GALE c.1004G>A variant is predicted to result in the amino acid substitution p.Arg335His. This variant has been reported in the compound heterozygous state in two individuals with galactosaemia epimerase deficiency (Park et al 2005. PubMed ID: 16301867; 2005. PubMed ID: 16302980). Arg335 is located on α-helix 10 on the protein surface (McCorvie et al. 2013. PubMed ID: 23644136). Functional studies showed that this variant causes mild defects in enzyme activity (Timson et al. 2005. PubMed ID: 16302980; Bang YL et al 2009. PubMed ID: 19250319). This variant is reported in 0.0054% of alleles in individuals of East Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-24122482-C-T). This variant is interpreted as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at